Hesperetin

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Metabolite of Hesperidin

2.60

2.6

175.82 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

184.45 Ų [M+Na]+ [CCS Type: DT; Method: stepped-field]

169.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

177.9 Ų [M-H]-

This chemical does not meet GHS hazard criteria for 97.9% (92 of 94) of all reports.

Not Classified

Aggregated GHS information provided per 94 reports by companies from 3 notifications to the ECHA C&L Inventory.

This chemical does not meet GHS hazard criteria for 100% (2 of 2) of all reports.

Not Classified

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Commission Regulation (EC) No 1565/2000 (Repealed by Com. Implementing Reg. (EU) No 872/2012)

4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2S)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Not Classified

Not Classified

Hesperetin is a cholesterol lowering flavanoid found in a number of citrus juices. It appears to reduce cholesteryl ester mass and inhibit apoB secretion by up to 80%. Hesperetin may have antioxidant, anti-inflammatory, anti-allergic, hypolipidemic, vasoprotective and anticarcinogenic actions.

Hesperetin reduces or inhibits the activity of acyl-coenzyme A:cholesterol acyltransferase genes (ACAT₁ and ACAT₂) and it reduces microsomal triglyceride transfer protein (MTP) activity. Hesperetin also seems to upregulate the LDL receptor. This leads to the reduced assembly and secretion of apoB-containing lipoproteins and enhanced reuptake of those lipoproteins, thereby lowering cholesterol levels.